Drug Combinations; Dydrogesterone/pharmacology; Estradiol/pharmacology; Estrogen Replacement Therapy; Female; Humans
Abstract :
[en] Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy whenever possible. The goals are to potentially minimize the risk of breast cancer, the danger of venous or arterial thrombosis and the glucose and lipid metabolic disturbances. Nevertheless, the preparation should efficaciously oppose to endometrial hyperplasia and yield a high degree of amenorrhea.
Disciplines :
Pharmacy, pharmacology & toxicology Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Gaspard, Ulysse ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Language :
French
Title :
Le medicament du mois. Femoston Low (0,5 mg d'estradiol plus 2,5 mg de dydrogesterone) comme traitement hormonal de substitution a la menopause.
Alternative titles :
[en] Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy
Publication date :
2011
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Gaspard U, van den Brûle F. - La substitution hormonale postménopausique : recommandations pratiques. Rev Med Liège, 1999, 54, 481-488. (Pubitemid 29287588)
van den Brûle F, Lifrange E, Pintiaux A, et al. - Hormonosubstitution postménopausique et risque de cancer mammaire : une mise à jour. Rev Med Liège, 2003, 58, 254-260.
van den Brûle F, Gaspard U. - Modifications corporelles à la ménopause : impact des thérapeutiques. Rev Med Liège, 2003, 58, 734-740.
Gaspard U, van den Brûle F. - Risques liés à la ménopause et traitement hormonal de la femme diabétique. Rev Med Liège, 2005, 60, 586-589.
Gaspard U, van den Brûle F, Pintiaux A, Foidart JM. - Balance bénéfice/risque du traitement oestroprogestatif postménopausique en péril dans l'étude Women's Health Initiative : attitude pratique du clinicien. Rev Med Liège, 2002, 57, 556-562.
Pintiaux A, Van den Brûle F, Foidart JM, Gaspard U. - Place du traitement substitutif de la ménopause 1 an après la publication des résultats de l'étude WHI (Women's Health Initiative). Rev Med Liège, 2003, 58, 572-575.
Gaspard U, Dubois M. - Actualités thérapeutiques en gynécologie : approches fonctionnelles. Rev Med Liège, 2007, 62, 423-427. (Pubitemid 351525751)
Gaspard U. - Prévention des troubles coronaires par le traitement hormonal précoce à la ménopause: une idée qui s'impose à nouveau. J Gynecol Obstet Biol Reprod, 2008, 37, 340-345.
Lenfant F, Trémollières F, Gourdy P, Arnal JF. - Timing of the vascular actions of estrogens in experimental and human studies : Why protective early, and not when delayed ? Maturitas, 2011, 68, 165-173.
Gaspard U, Van Den Brûle F. - La contraception oestroprogestative continue : enfin sans les règles. Rev Med Liège, 2006, 61, 23-26. (Pubitemid 43211759)
Utian WH, Bachmann GA, Cahill EB, et al. - Estrogen and progestogen use in postmenopausal women : 2010 position statement of the North American Menopause Society. Menopause, 2010, 17, 242-255.
Schenck-Gustafsson K, Brincat M, Erel CT, et al. - EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas, 2011, 68, 94-97.
Schindler AE. - Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas, 2009, 65 (Suppl 1), S3-11.
Mueck AO, Seeger H, Bühling KJ. - Use of dydrogesterone in hormone replacement therapy. Maturitas, 2009, 65 (Suppl 1), S51-60.
Gaspard UJ, Wery OJ, Scheen AJ, et al.- Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric, 1999, 2, 93-100. (Pubitemid 29333648)
Fournier A.- Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. Menopause Int, 2010, 16, 23-32.
Ettinger B, Genant HK, Steiger P, Madvig P. - Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol, 1992, 166, 479-488.
Fournier A, Berrino F, Clavel-Chapelon F. - Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat, 2008, 107, 103-111. (Pubitemid 350179584)
Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. - Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol, 2009, 27, 5138-5143.
Schneider C, Jick SS, Meier CR. - Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric, 2009, 12, 514-524.
Schneider C, Jick SS, Meier CR. - Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric, 2009, 12, 445-453.
Olié V, Canonico M, Scarabin P Y. - Postmenopausal hormone therapy and venous thromboembolism. Thrombosis Research, 2011, 127, S26-S29.
Stevenson JC, Durand G, Kahler E, Pertynski T. - Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas, 2010, 67, 227-232.
Bergeron C, Nogales FF, Rechberger T, et al. - Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17β-oestradiol and 2.5mg dydrogesterone : protection of the endometrium and amenorrhoea rate. Maturitas, 2010, 66, 201-205.